{
    "ticker": "MDXG",
    "name": "MediWound Ltd.",
    "description": "MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing innovative therapies for advanced wound care and tissue regeneration. Founded in 2001 and headquartered in Yavne, Israel, the company is committed to providing solutions that address unmet medical needs in the treatment of chronic and acute wounds. MediWound's flagship product, NexoBrid, is a unique enzymatic debridement agent designed to remove devitalized tissue from severe burns and other wounds without the need for surgical intervention. The product has received regulatory approvals in multiple countries, including the FDA in the United States, offering healthcare professionals a revolutionary tool for burn treatment. In addition to NexoBrid, MediWound is developing other advanced wound care products, including EscharEx, a novel topical treatment for chronic and hard-to-heal wounds. The company leverages its proprietary technology platform to innovate and create effective treatments that enhance patient outcomes and improve healthcare efficiency. MediWound is dedicated to clinical research and development, constantly seeking to expand its product portfolio and improve the lives of patients suffering from complex wound-related conditions.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Yavne, Israel",
    "founded": "2001",
    "website": "https://www.mediwound.com",
    "ceo": "Gal Cohen",
    "social_media": {
        "linkedin": "https://www.linkedin.com/company/medi-wound-ltd"
    },
    "investor_relations": "https://investors.mediwound.com",
    "key_executives": [
        {
            "name": "Gal Cohen",
            "position": "CEO"
        },
        {
            "name": "Ariel S. S. Koren",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Wound Care Products",
            "products": [
                "NexoBrid",
                "EscharEx"
            ]
        }
    ],
    "seo": {
        "meta_title": "MediWound Ltd. | Innovative Wound Care Solutions",
        "meta_description": "Discover MediWound Ltd., a biopharmaceutical company specializing in advanced wound care and tissue regeneration products. Learn about our innovative therapies for chronic and acute wounds.",
        "keywords": [
            "MediWound",
            "NexoBrid",
            "EscharEx",
            "Wound Care",
            "Biotechnology",
            "Pharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is MediWound known for?",
            "answer": "MediWound is known for developing innovative therapies for advanced wound care, particularly its product NexoBrid."
        },
        {
            "question": "Who is the CEO of MediWound?",
            "answer": "Gal Cohen is the CEO of MediWound Ltd."
        },
        {
            "question": "Where is MediWound headquartered?",
            "answer": "MediWound is headquartered in Yavne, Israel."
        },
        {
            "question": "What are MediWound's main products?",
            "answer": "MediWound's main products include NexoBrid and EscharEx."
        },
        {
            "question": "When was MediWound founded?",
            "answer": "MediWound was founded in 2001."
        }
    ],
    "competitors": [
        "AXGN",
        "CRMD",
        "AVH",
        "APDN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "VRTX"
    ]
}